Clarity Pharmaceuticals Hits Enrollment Target in Phase III AMPLIFY Trial for Prostate Cancer Imaging
Event summary
- Clarity Pharmaceuticals' Phase III AMPLIFY trial exceeded its target of 220 participants, enrolling more than planned in just 9 months.
- The trial evaluates 64Cu-SAR-bisPSMA PET/CT for detecting prostate cancer recurrence in patients with PSA levels above 0.2 ng/mL.
- AMPLIFY is a pivotal study intended to support FDA approval for 64Cu-SAR-bisPSMA as a diagnostic imaging agent.
- The company has imaged approximately 600 prostate cancer patients with 64Cu-SAR-bisPSMA, with 350 scans conducted in the last year alone.
- The CLARIFY Phase III trial is expected to close recruitment in 2026, with results aimed at supporting FDA approval for definitive therapy candidates.
The big picture
Clarity Pharmaceuticals' rapid enrollment in the AMPLIFY trial underscores the unmet need for advanced prostate cancer diagnostics. The company's proprietary SAR-bisPSMA technology aims to outperform standard-of-care PSMA PET imaging, potentially expanding the diagnostic market. Success in these pivotal trials could position Clarity as a key player in the growing radiopharmaceutical sector, particularly in theranostic applications for prostate cancer.
What we're watching
- Regulatory Pathway
- Whether the AMPLIFY trial results will meet FDA standards for approval, given the strong competition from existing SOC PSMA PET products.
- Market Differentiation
- How Clarity Pharmaceuticals will position 64Cu-SAR-bisPSMA against established diagnostic imaging agents in the prostate cancer space.
- Commercialization Timing
- The pace at which Clarity can transition from clinical trials to commercialization, particularly with the pending CLARIFY trial results and ongoing SECuRE trial.
Related topics